Biotricity Confirms Aggressive 1-for-100 Reverse Stock Split

summarizeSummary

Biotricity has filed a definitive statement confirming a highly aggressive 1-for-100 reverse stock split, a critical move aimed at increasing its share price to meet NASDAQ listing requirements and improve marketability, especially given its current "going concern" status.

check_boxKey Events

• Definitive Reverse Stock Split Approval

  The Board of Directors and a majority of consenting shareholders have definitively approved a 1-for-100 reverse stock split, confirming the action previously disclosed in a preliminary filing on May 29, 2026.

• Strategic Goal: NASDAQ Relisting

  The primary purpose of the reverse split is to increase the per-share price to meet NASDAQ Capital Markets listing requirements and improve the marketability of the common stock, which currently trades as a 'penny stock'.

• Fractional Shares Rounded Up

  Any fractional shares resulting from the reverse split will be rounded up to the nearest whole share, ensuring no cash payments for fractional interests.

• No Change to Authorized Shares

  The reverse stock split will not alter the total number of authorized shares of common stock.

auto_awesomeAnalysis

This definitive filing confirms the previously announced 1-for-100 reverse stock split. This aggressive action is a critical move for Biotricity, a micro-cap company currently carrying a "going concern" warning. The primary goal is to boost the per-share price to meet NASDAQ listing requirements and enhance marketability, as the stock currently trades as a "penny stock." While intended to improve the company's market standing, reverse splits of this magnitude are often viewed negatively by investors, as they can signal underlying financial distress and frequently fail to sustain higher stock prices in the long term. The market will now watch for the effective date of the split and its immediate impact on trading.